General Information of Disease (ID: DIS4UQOT)

Disease Name Psychotic disorder
Synonyms mental or behavioral disorder; mental or behavioural disorder; psychosis
Disease Class 6A20-6A25: Psychotic disorder
Definition
An abnormal condition of the mind that involves a loss of contact with reality. People experiencing psychosis may exhibit personality changes and thought disorder. Depending on its severity, this may be accompanied by unusual or bizarre behavior, as well as difficulty with social interaction and impairment in carrying out daily life activities.
Disease Hierarchy
DIS3J5R8: Mental disorder
DISH2ERD: Cognitive impairment
DIS4UQOT: Psychotic disorder
ICD Code
ICD-11
ICD-11: 6A20-6A25
Expand ICD-9
2.90E+29
Disease Identifiers
MONDO ID
MONDO_0005485
MESH ID
D011618
UMLS CUI
C0033975
MedGen ID
19568
HPO ID
HP:0000709
SNOMED CT ID
69322001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 12 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Chlorpromazine DMBGZI3 Approved Small molecular drug [1]
Chlorprothixene DMY0KGJ Approved Small molecular drug [2]
Fluphenazine DMIT8LX Approved Small molecular drug [3]
Haloperidol DM96SE0 Approved Small molecular drug [4]
Levomepromazine DMIKFEL Approved Small molecular drug [5]
Meglitinides DM1OFHN Approved Small molecular drug [6]
Paliperidone DM7NPJS Approved Small molecular drug [7]
Perazine DM2AOTZ Approved Small molecular drug [5]
Perospirone DMVHJLX Approved Small molecular drug [8]
Promazine DMZAL7W Approved Small molecular drug [9]
Reserpine DM6VM38 Approved Small molecular drug [10]
Triflupromazine DMKFQJP Approved Small molecular drug [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 Drug(s)
This Disease is Treated as An Indication in 20 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Bis(olanzapine) pamoate monohydrate DME76AP Phase 3 NA [5]
AGN-2979 DMLQRFO Phase 2 Small molecular drug [12]
CGS-15873A DMKS7RJ Phase 2 Small molecular drug [13]
L-745,870 DMTGR25 Phase 2 Small molecular drug [14]
Mazapertine succinate DMJKHVX Phase 2 Small molecular drug [15]
Oleoyl-estrone DM0RA8F Phase 2 Small molecular drug [16]
ORG-13011 DMAWXJT Phase 2 Small molecular drug [17]
ORG-25935 DMWN2EC Phase 2 Small molecular drug [18]
PD-143188 DMXAH4G Phase 2 Small molecular drug [19]
ROXINDOLE DM15QL9 Phase 2 Small molecular drug [20]
SDZ-MAR-327 DM2YIOE Phase 2 Small molecular drug [21]
Vabicaserin DM9GZW6 Phase 2 Small molecular drug [22]
Dihydrexidine DMACPQO Phase 1/2 Small molecular drug [23]
1192U90 DM5IPHE Phase 1 Small molecular drug [24]
AMG 581 DMH1KAF Phase 1 NA [25]
ATON-005 DMNEWFY Phase 1 NA [26]
INT-0022 DMT4MLD Phase 1 NA [27]
NPT088 DM157TU Phase 1 NA [16]
RG7410 DMKMS4W Phase 1 NA [28]
SA-5845 DM6XZRL Phase 1 NA [29]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Drug(s)
This Disease is Treated as An Indication in 32 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
BMS-181100 DM0HR5W Discontinued in Phase 3 Small molecular drug [30]
A-437203 DMEG240 Discontinued in Phase 2 Small molecular drug [31]
ADX-10061 DMZS2M4 Discontinued in Phase 2 NA [32]
AVE1625 DMXNK0J Discontinued in Phase 2 Small molecular drug [33]
Lu-35138 DMQ7A35 Discontinued in Phase 2 NA [34]
Panamesine DM6TPCJ Discontinued in Phase 2 Small molecular drug [35]
SAVOXEPIN MESYLATE DMQMA17 Discontinued in Phase 2 Small molecular drug [36]
AVE-5997EF DM5FDX2 Discontinued in Phase 1 Small molecular drug [37]
Berupipam DMU1YON Discontinued in Phase 1 Small molecular drug [38]
BTS-73947 DMGVEJ6 Discontinued in Phase 1 NA [39]
DU-29894 DMN9KXU Discontinued in Phase 1 NA [40]
DUP-734 DMI5EPB Discontinued in Phase 1 Small molecular drug [41]
Gevotroline DM520D8 Discontinued in Phase 1 Small molecular drug [42]
Odapipam DMZN6F3 Discontinued in Phase 1 Small molecular drug [43]
Ordopidine DMQBURK Discontinued in Phase 1 Small molecular drug [44]
S-18327 DML6A8X Discontinued in Phase 1 NA [45]
S-33138 DM1R8Z7 Discontinued in Phase 1 Small molecular drug [46]
SSR-146977 DMR9JA8 Discontinued in Phase 1 Small molecular drug [47]
A-69024 DMPL1OV Terminated Small molecular drug [49]
BIMG80 DM9X1DZ Terminated NA [50]
FH-510 DMJ35RC Terminated Small molecular drug [51]
NE-033 DMEH50J Terminated NA [52]
NGD-93-1 DMFA26E Terminated NA [53]
NNC-22-0031 DMK7BV9 Terminated Small molecular drug [54]
NPC-16377 DM35RTJ Terminated Small molecular drug [55]
NPC-18166 DMAIH90 Terminated NA [56]
Org-10490 DMUGC2X Terminated NA [57]
Org-30035 DMMA92L Terminated NA [58]
RGH-2721 DMBCIPO Terminated NA [59]
RWJ-25730 DMRQZWN Terminated Small molecular drug [60]
Y-20024 DM7TQYF Terminated Small molecular drug [61]
YM-43611 DMWI094 Terminated NA [62]
------------------------------------------------------------------------------------
⏷ Show the Full List of 32 Drug(s)
This Disease is Treated as An Indication in 1 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
S-33084 DMWQ3TH Preclinical Small molecular drug [48]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 5 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ABS-201 DMD0Z2H Investigative Small molecular drug [63]
CLR-151 DM9LSOW Investigative NA [64]
NESS-200P DMKHV6Y Investigative NA [65]
PJ-016 DMUZHJO Investigative NA [65]
SDZ-208911 DMLPRU4 Investigative Small molecular drug [66]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 121 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ARSB TTESQTG Limited Biomarker [67]
ATP2A2 TTE6THL Limited Genetic Variation [68]
BRD1 TTT09OB Limited Genetic Variation [69]
CCL11 TTCF05Y Limited Biomarker [70]
CHRNA4 TT4H1MQ Limited Genetic Variation [71]
CHRNA7 TTLA931 Limited Genetic Variation [72]
CNTF TTGEM5Q Limited Genetic Variation [73]
DPYSL2 TTZCW3T Limited Genetic Variation [74]
EIF2AK1 TTRUJBV Limited Genetic Variation [75]
ELK3 TT5OJMV Limited Genetic Variation [76]
FES TTLBY21 Limited Biomarker [77]
GABRA1 TT1MPAY Limited Biomarker [78]
GABRG2 TT06RH5 Limited Biomarker [78]
GABRG3 TTEX6LM Limited Genetic Variation [79]
GRIN2A TTKJEMQ Limited Biomarker [80]
HAL TTXQOZW Limited Biomarker [81]
HRH1 TTTIBOJ Limited Genetic Variation [82]
HRH3 TT9JNIC Limited Genetic Variation [71]
HTR7 TTO9X1H Limited Biomarker [83]
KCNN3 TT9JH25 Limited Genetic Variation [84]
MAD1L1 TTNE9U7 Limited Genetic Variation [85]
MAOA TT3WG5C Limited Biomarker [86]
MTNR1B TT32JK8 Limited Genetic Variation [87]
OXTR TTSCIUP Limited Genetic Variation [88]
PCSK7 TTD30LY Limited Biomarker [89]
PPT1 TTSQC14 Limited Biomarker [90]
PRCP TTTJZ4M Limited Biomarker [91]
RGS6 TTJ96M8 Limited Genetic Variation [92]
RTN4R TTVRZUO Limited Genetic Variation [93]
SCN11A TTN9VTF Limited Altered Expression [94]
SF3B1 TTL2WUI Limited Genetic Variation [95]
SLC18A2 TTNZRI3 Limited Genetic Variation [96]
SLC1A1 TTG2A6F Limited Genetic Variation [97]
TPH1 TTZSJHV Limited Biomarker [86]
WAS TTE8T73 Limited Biomarker [98]
GRM7 TT0I76D Disputed Biomarker [99]
GRM8 TT0IFKL Disputed Biomarker [99]
TAAR1 TTIU98M Disputed Biomarker [100]
UBE3A TTUZX6V Disputed Biomarker [101]
BPI TTXCSDR moderate Genetic Variation [102]
GAD2 TT7UY6K moderate Genetic Variation [103]
GRIN2B TTN9D8E moderate Altered Expression [104]
HLA-A TTHONFT moderate Genetic Variation [105]
KMO TTIY56R moderate Genetic Variation [106]
PDGFRB TTI7421 moderate Genetic Variation [107]
PHF8 TT81PFE moderate Genetic Variation [108]
RGS4 TTGTKX9 moderate Genetic Variation [109]
SMC2 TTS8D17 moderate Genetic Variation [110]
ABCB1 TT3OT40 Strong Biomarker [111]
ACTG1 TTGAZF9 Strong Biomarker [112]
ADCY5 TTN64VU Strong Biomarker [113]
AVP TTJ8EWH Strong Biomarker [114]
CACNA1C TTZIFHC Strong Biomarker [115]
CALR TTUZ7OA Strong Genetic Variation [116]
CCKAR TTCG0AL Strong Biomarker [117]
CD34 TTZAVYN Strong Biomarker [118]
CD40 TT1ERKL Strong Biomarker [119]
CHN2 TT39YVO Strong Genetic Variation [120]
CNR1 TT6OEDT Strong Altered Expression [121]
CRHR1 TT7EFHR Strong Altered Expression [122]
CSF2RB TTPYS82 Strong Biomarker [123]
CYP2B6 TTMH124 Strong Biomarker [124]
CYP2D6 TTVG215 Strong Biomarker [125]
DAO TT7Y3EJ Strong Genetic Variation [126]
DAPK3 TTERVQN Strong Genetic Variation [127]
DRD1 TTZFYLI Strong Biomarker [128]
DRD3 TT4C8EA Strong Genetic Variation [129]
DRD5 TTS2PH3 Strong Biomarker [130]
FGFR2 TTGJVQM Strong Biomarker [131]
GABRB2 TTZA1NY Strong Biomarker [132]
GAD1 TTKGEP3 Strong Altered Expression [133]
GADD45B TTMDW9L Strong Biomarker [134]
GCH1 TTLSWP6 Strong Biomarker [135]
GLP2R TT1YWO5 Strong Genetic Variation [136]
GLUL TTURQ2G Strong Biomarker [137]
GRIA3 TT82EZV Strong Genetic Variation [138]
GRIK3 TTNP6O2 Strong Genetic Variation [139]
GRIK4 TTQV6BO Strong Genetic Variation [140]
GRIN1 TTLD29N Strong Genetic Variation [141]
GRM2 TTXJ47W Strong Biomarker [142]
GRM5 TTHS256 Strong Biomarker [143]
GRN TT0LWE3 Strong Genetic Variation [144]
GSTA1 TT4P8DE Strong Biomarker [145]
GSTP1 TT40K12 Strong Genetic Variation [146]
HBA2 TTQO71U Strong Altered Expression [147]
HDAC2 TTSHTOI Strong Biomarker [148]
HLA-B TTGS10J Strong Biomarker [149]
HPGDS TTCYE56 Strong Biomarker [145]
HTR1A TTSQIFT Strong Biomarker [150]
HTR1B TTK8CXU Strong Biomarker [130]
HTR5A TTRUFDT Strong Genetic Variation [151]
HTR6 TTJS8PY Strong Biomarker [152]
KCNH2 TTQ6VDM Strong Biomarker [153]
LEP TTBJEZ5 Strong Altered Expression [154]
MAPT TTS87KH Strong Biomarker [155]
MECP2 TTTAU9R Strong Genetic Variation [156]
MGAT1 TTYJRN5 Strong Genetic Variation [157]
NFKB1 TTUIZKC Strong Biomarker [119]
NQO2 TTJLP0R Strong Biomarker [158]
NR3C1 TTOZRK6 Strong Genetic Variation [122]
NTRK1 TTTDVOJ Strong Biomarker [130]
OPRM1 TTKWM86 Strong Biomarker [159]
PAH TTGSVH2 Strong Biomarker [160]
PAWR TT3I4WV Strong Biomarker [161]
PBRM1 TTH8ZRL Strong Biomarker [162]
PDE10A TTJW4LU Strong Biomarker [163]
PRKCA TTFJ8Q1 Strong Biomarker [164]
PRNP TTY5F9C Strong Genetic Variation [165]
PTPRC TTUS45N Strong Biomarker [118]
RPS6KA3 TTUM2ZR Strong Altered Expression [166]
SLC12A6 TT8DFHE Strong Genetic Variation [167]
SLC6A3 TTVBI8W Strong Biomarker [168]
SLC6A9 TTHJTF7 Strong Biomarker [157]
SNAP25 TTYQWA0 Strong Biomarker [130]
SP1 TTZEP6S Strong Biomarker [169]
TDO2 TTXNCBV Strong Biomarker [170]
TIRAP TTKU0LS Strong Biomarker [171]
TPH2 TT3KLDP Strong Genetic Variation [86]
TRPM2 TTEBMN7 Strong Biomarker [172]
TSPO TTPTXIN Strong Altered Expression [173]
TYR TTULVH8 Strong Biomarker [174]
------------------------------------------------------------------------------------
⏷ Show the Full List of 121 DTT(s)
This Disease Is Related to 5 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
KCNH7 DT3WXPI Limited Biomarker [153]
SLC27A5 DT0TQS3 Limited Biomarker [175]
SLC12A2 DTHKL3Q Strong Biomarker [176]
SLC24A3 DTO18LP Strong Genetic Variation [120]
SLC39A3 DTH08M7 Strong Biomarker [177]
------------------------------------------------------------------------------------
This Disease Is Related to 7 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
ALAS2 DE437BY Limited Biomarker [67]
NMNAT2 DE2HB58 Limited Genetic Variation [178]
SCLY DEH4TD6 Limited Genetic Variation [179]
THOP1 DE95LJC Limited Genetic Variation [180]
ADH1B DEEN9RD Strong Genetic Variation [181]
PGPEP1 DEVDR46 Strong Genetic Variation [102]
SAT1 DEMWO83 Strong Biomarker [182]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)
This Disease Is Related to 164 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ADAMTS2 OTTK22NO Limited Biomarker [183]
ALG9 OT5V9PIR Limited Genetic Variation [184]
ALYREF OTOF2ADD Limited Biomarker [185]
ARFGEF1 OTPAU0L4 Limited Biomarker [186]
ARID2 OTIRJXWM Limited Biomarker [186]
ASAP1 OT4DLRYY Limited Biomarker [187]
ASAP2 OTGEXULW Limited Biomarker [187]
ASXL1 OTX931AW Limited Genetic Variation [95]
BAG1 OTRQNIA4 Limited Genetic Variation [188]
CCRL2 OT5PX0RX Limited Genetic Variation [75]
CDT1 OTVY53VG Limited Biomarker [189]
CGAS OTJYIXNB Limited Biomarker [190]
CHGB OT7SAQT2 Limited Biomarker [191]
CHP1 OTHTXN1A Limited Biomarker [192]
CHPT1 OT4FJ0K3 Limited Genetic Variation [193]
CHRNA6 OTT6W86V Limited Biomarker [194]
CLDN5 OTUX60YO Limited Biomarker [195]
CLINT1 OTQ1CQA2 Limited Biomarker [196]
CNRIP1 OTXPWJ56 Limited Altered Expression [197]
CPZ OT5HUR28 Limited Biomarker [198]
CSMD2 OT541Z3W Limited Genetic Variation [180]
CXCL17 OTRCEVIZ Limited Biomarker [199]
DHDDS OTVLYBUS Limited Genetic Variation [193]
DRP2 OTWR7WGU Limited Genetic Variation [74]
DYM OTQ670WI Limited Biomarker [199]
EBPL OT59J1GY Limited Genetic Variation [76]
EDA OTAKS5WS Limited Biomarker [200]
INSRR OT3F75WA Limited Genetic Variation [201]
KALRN OT8WRCBH Limited Biomarker [202]
KCNK5 OT68V64E Limited Biomarker [203]
KRT7 OTLT3JFN Limited Genetic Variation [179]
LCN1 OT8BWXTV Limited Genetic Variation [204]
LGI1 OTPS77HO Limited Biomarker [205]
LRPAP1 OT6DVD2Q Limited Biomarker [206]
LRRTM1 OTKI3IU9 Limited Biomarker [207]
MAPK4 OTVWWUYS Limited Genetic Variation [208]
MRPS30 OTDXIAGG Limited Biomarker [187]
MTPAP OT6HQ02S Limited Biomarker [187]
NAXE OTRZPISQ Limited Genetic Variation [209]
ND4 OT4RQVAA Limited Genetic Variation [210]
ND5 OT45LW1K Limited Genetic Variation [210]
NPL OTA7P0TO Limited Biomarker [211]
NRSN1 OT1KKXC8 Limited Biomarker [192]
NRXN1 OTJN1JQA Limited Genetic Variation [212]
PAPOLA OTPHD65D Limited Biomarker [187]
PCDH11X OTLICG18 Limited Genetic Variation [213]
PDAP1 OTJSWMOD Limited Biomarker [187]
PDP1 OT82RTMT Limited Biomarker [214]
PDSS1 OTXGVHAB Limited Biomarker [215]
PIK3C2A OTFBU4GD Limited Genetic Variation [85]
PPP1R1B OTSIJMQ9 Limited Biomarker [216]
PRICKLE2 OTWBA48T Limited Biomarker [217]
PRSS2 OTOMVUWL Limited Altered Expression [218]
PYCR1 OTQHB52T Limited Genetic Variation [219]
REM1 OTUXL0HC Limited Biomarker [220]
RGS9 OTRA1LOC Limited Altered Expression [221]
RTN3 OTGZ51QF Limited Genetic Variation [188]
SAFB OTGRV2LW Limited Genetic Variation [188]
SEMG1 OT6Z4BPQ Limited Biomarker [191]
SEPHS1 OTZ19I59 Limited Biomarker [215]
SH2B2 OTEDHHDH Limited Biomarker [222]
SKAP2 OTSF44KP Limited Biomarker [223]
SLAMF1 OTBTT3ZQ Limited Biomarker [224]
SNX7 OTO8J1D0 Limited Altered Expression [225]
SPEN OT37A2MD Limited Biomarker [226]
SV2C OTIH108W Limited Biomarker [227]
TAL1 OTX4K6QZ Limited Genetic Variation [179]
TBCA OTCCWMGK Limited Biomarker [228]
TBX4 OTW58FG4 Limited Biomarker [215]
TGIF1 OTN9VHAG Limited Genetic Variation [229]
TMED2 OTBLO7RW Limited Biomarker [192]
TNRC6A OT493IOM Limited Genetic Variation [230]
TPPP OTCFMSUF Limited Biomarker [192]
TTLL6 OTHBM3DX Limited Genetic Variation [85]
ARID3B OTUP9MS4 Disputed Genetic Variation [231]
GAB2 OTBFN705 Disputed Biomarker [232]
GSTM5 OTMMBFY8 Disputed Biomarker [233]
MCPH1 OTYT3TT5 Disputed Genetic Variation [234]
PPM1K OTNZ4N4E Disputed Genetic Variation [231]
PTPN4 OT6SXU5Y Disputed Genetic Variation [235]
ADAM19 OTH88TXU moderate Genetic Variation [102]
AMPD3 OT5SP1KJ moderate Genetic Variation [236]
CLDN11 OTNN6UTL moderate Genetic Variation [102]
CNTNAP2 OT48T2ZP moderate Genetic Variation [102]
DIPK1A OTWS5V2I moderate Genetic Variation [102]
FGF9 OT2SKDGM moderate Altered Expression [237]
KCNMB2 OTBXUQGK moderate Genetic Variation [105]
MED12 OTQZ4D2X moderate Genetic Variation [238]
NALCN OTWY7DS0 moderate Genetic Variation [102]
NCKAP5 OT5JOYZS moderate Genetic Variation [102]
PAFAH1B1 OT9T2TCJ moderate Genetic Variation [95]
RIN2 OTCY73U9 moderate Genetic Variation [102]
SAA2 OTYAVJWG moderate Genetic Variation [102]
SPTLC1 OTN0Z98K moderate Genetic Variation [105]
ACOT7 OT7C68YV Strong Biomarker [112]
ACTBL2 OTD6B81U Strong Biomarker [112]
ACTG2 OTRDWUO0 Strong Biomarker [112]
ADARB1 OTGKSZEV Strong Biomarker [239]
ANK3 OTJ3IRBP Strong Altered Expression [240]
APOBEC3A OTYO6F5P Strong Biomarker [241]
APOBEC3C OTPL0AI1 Strong Biomarker [241]
ARHGAP26 OTNGQU7A Strong Biomarker [242]
ARHGEF7 OT9BPJCL Strong Biomarker [119]
ASCC1 OTH4VAP9 Strong Biomarker [119]
BCL9 OTRBIPR4 Strong Biomarker [243]
CDH17 OT9EV2XK Strong Biomarker [244]
COL21A1 OT7GS82E Strong Genetic Variation [120]
CPLX1 OT7UIGTP Strong Biomarker [130]
CPLX2 OTU5QWFH Strong Biomarker [130]
CPVL OTOJL31C Strong Genetic Variation [120]
DAOA OT7NFEO6 Strong Genetic Variation [245]
DGCR8 OT62LXE4 Strong Biomarker [246]
DISC1 OT43AW4H Strong Biomarker [247]
DNASE1L3 OTEUIMC2 Strong Biomarker [248]
DTNBP1 OT9UQT2S Strong Genetic Variation [249]
EEF1A2 OT9Z23K5 Strong Biomarker [250]
FEZ1 OTWCXPRE Strong Biomarker [251]
FHL5 OT6C00Z1 Strong Biomarker [112]
FTL OTYQA8A6 Strong Biomarker [252]
GNA12 OT3IRZH3 Strong Biomarker [244]
GNB1L OTXSUD8R Strong Biomarker [253]
GPR52 OTPR99C7 Strong Biomarker [254]
HLA-E OTX1CTFB Strong Biomarker [255]
KCNH6 OTQ52G7V Strong Biomarker [153]
KIDINS220 OTLBH2MA Strong Biomarker [256]
LMOD2 OTFXHQFL Strong Biomarker [257]
LRP8 OTZ71YV2 Strong Genetic Variation [258]
ME2 OTO4LL76 Strong Biomarker [259]
MEF2A OTV2SF6E Strong Biomarker [260]
NAT8L OTA96AVN Strong Biomarker [261]
NDE1 OT2N8Q17 Strong Biomarker [262]
NHS OTKE8QAT Strong Biomarker [263]
NPAS1 OTZKO6ZN Strong Biomarker [264]
NPAS3 OT8D1ILB Strong Biomarker [265]
OLIG2 OTMCN6D3 Strong Genetic Variation [266]
PAK3 OT80M3BV Strong Biomarker [267]
PAK5 OT32WQGL Strong Altered Expression [268]
PCDH19 OTSOW3MV Strong Genetic Variation [269]
PCNT OTW4Z65J Strong Biomarker [270]
PGBD1 OTSJX9UU Strong Genetic Variation [258]
PICK1 OT8QE6EU Strong Biomarker [271]
PITRM1 OTDEAZ8K Strong Genetic Variation [272]
PLA2G6 OT5FL0WU Strong Biomarker [172]
PLAA OTZ7NJGA Strong Genetic Variation [258]
POTEM OT7L2HGH Strong Biomarker [112]
PPP3CC OT0AQD93 Strong Biomarker [273]
PVALB OTZW1WVQ Strong Biomarker [274]
RELN OTLKMW1O Strong Biomarker [275]
SELENBP1 OT3NZNTR Strong Altered Expression [276]
SEPTIN2 OT3G33TM Strong Genetic Variation [277]
SHANK1 OTK8PV0S Strong Biomarker [278]
SOBP OTI8OO0M Strong Biomarker [279]
SP8 OTLCMPKH Strong Biomarker [162]
ST3GAL1 OTFCO8QX Strong Biomarker [280]
ST6GALNAC1 OT3JQD99 Strong Biomarker [281]
TAOK2 OTNUMOZ1 Strong Genetic Variation [258]
TBX1 OTQLBPRA Strong Biomarker [282]
TCF4 OTB9ASTK Strong Genetic Variation [283]
TENM4 OT91K3FC Strong Biomarker [284]
TET1 OTZDHT1D Strong Altered Expression [285]
TMEM182 OTVDIS2V Strong Genetic Variation [120]
TRIM9 OTKYG33W Strong Genetic Variation [120]
TRRAP OT68OI2Y Strong Genetic Variation [286]
SPAST OTIF3AJI Definitive Biomarker [287]
------------------------------------------------------------------------------------
⏷ Show the Full List of 164 DOT(s)

References

1 Chlorpromazine FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016149.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 204).
4 Haloperidol FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 94).
7 Paliperidone FDA Label
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7556).
9 Promazine FDA Label
10 Reserpine FDA Label
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4330).
12 Antidepressant-like action of AGN 2979, a tryptophan hydroxylase activation inhibitor, in a chronic mild stress model of depression in rats. Eur Neuropsychopharmacol. 2001 Oct;11(5):351-7.
13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001412)
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3303).
15 Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors. J Med Chem. 1998 Jun 4;41(12):1997-2009.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 ClinicalTrials.gov (NCT00000189) Gepirone vs Placebo in Treatment of Cocaine Dependence - 3. U.S. National Institutes of Health.
18 ClinicalTrials.gov (NCT00725725) Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705AM3)(TERMINATED). U.S. National Institutes of Health.
19 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005971)
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 52).
21 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
22 ClinicalTrials.gov (NCT00768612) Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia. U.S. National Institutes of Health.
23 Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology. 2015 Jan;40(2):446-53.
24 1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects. Neuropsychopharmacology. 1996 Sep;15(3):231-42.
25 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800042300)
26 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032209)
27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033619)
28 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038118)
29 Preclinical evaluation of [11C]SA4503: radiation dosimetry, in vivo selectivity and PET imaging of sigma1 receptors in the cat brain. Ann Nucl Med. 2000 Aug;14(4):285-92.
30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8).
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012940)
32 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001476)
33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020616)
34 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001428)
36 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000647)
37 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018413)
38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004006)
39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008043)
40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001422)
41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001777)
42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001398)
43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006052)
44 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025217)
45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009651)
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014544)
47 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2133).
48 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 129).
49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002637)
50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006596)
51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002069)
52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004064)
53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002902)
54 NNC-19-1228 and NNC 22-0031, novel neuroleptics with a "mesolimbic-selective" behavioral profile. Psychopharmacology (Berl). 1997 Jan;129(2):168-78.
55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001997)
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004563)
57 ORG 10490: A new antipsychotic drug with 5-HT2 and DA antagonistic properties. ScienceDirect, Volume 6, Issue 2, January 1992, Pages 111.
58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002901)
59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004008)
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001430)
61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001374)
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005975)
63 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5308).
64 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215).
65 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
66 Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn SchmiedebergsArch Pharmacol. 1991 Sep;344(3):263-74.
67 Symptom-related attributional biases in schizophrenia and bipolar disorder.Cogn Neuropsychiatry. 2017 Jul;22(4):263-279. doi: 10.1080/13546805.2017.1314957. Epub 2017 Apr 19.
68 Loss of function mutations in ATP2A2 and psychoses: A case report and literature survey.Psychiatry Clin Neurosci. 2016 Aug;70(8):342-50. doi: 10.1111/pcn.12395. Epub 2016 Jun 3.
69 Identification of the BRD1 interaction network and its impact on mental disorder risk.Genome Med. 2016 May 3;8(1):53. doi: 10.1186/s13073-016-0308-x.
70 A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions.CNS Neurol Disord Drug Targets. 2019;18(2):124-140. doi: 10.2174/1871527317666181119115532.
71 A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans.Transl Psychiatry. 2019 Nov 18;9(1):309. doi: 10.1038/s41398-019-0639-7.
72 Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease.Neuromolecular Med. 2008;10(4):377-84. doi: 10.1007/s12017-008-8048-8. Epub 2008 Aug 12.
73 Schizophrenic psychoses and the CNTF null mutation.Neuroreport. 1998 Apr 20;9(6):981-3. doi: 10.1097/00001756-199804200-00005.
74 Association study of the dihydropyrimidinase-related protein 2 gene and methamphetamine psychosis.Ann N Y Acad Sci. 2006 Aug;1074:90-6. doi: 10.1196/annals.1369.008.
75 Prediction of Violence, Suicide Behaviors and Suicide Ideation in a Sample of Institutionalized Offenders With Schizophrenia and Other Psychosis.Front Psychol. 2018 Aug 7;9:1385. doi: 10.3389/fpsyg.2018.01385. eCollection 2018.
76 Social aversive conditioning in youth at clinical high risk for psychosis and with psychosis: An ERP study.Schizophr Res. 2018 Dec;202:291-296. doi: 10.1016/j.schres.2018.06.027. Epub 2018 Jun 21.
77 Can positive family factors be protective against the development of psychosis?.Psychiatry Res. 2011 Mar 30;186(1):28-33. doi: 10.1016/j.psychres.2010.05.015. Epub 2010 Jul 13.
78 Genetic association studies of methamphetamine use disorders: A systematic review and synthesis.Am J Med Genet B Neuropsychiatr Genet. 2009 Dec 5;150B(8):1025-49. doi: 10.1002/ajmg.b.30936.
79 Methylation profiling in individuals with uniparental disomy identifies novel differentially methylated regions on chromosome 15.Genome Res. 2010 Sep;20(9):1271-8. doi: 10.1101/gr.108597.110. Epub 2010 Jul 14.
80 Schizophrenia: Evidence implicating hippocampal GluN2B protein and REST epigenetics in psychosis pathophysiology.Neuroscience. 2015 Nov 19;309:233-42. doi: 10.1016/j.neuroscience.2015.07.038. Epub 2015 Jul 23.
81 A latent class analysis of psychotic symptoms in the general population.Aust N Z J Psychiatry. 2018 Jun;52(6):573-584. doi: 10.1177/0004867417744255. Epub 2017 Dec 13.
82 Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication.Psychopharmacology (Berl). 2011 Jul;216(2):257-65. doi: 10.1007/s00213-011-2211-x. Epub 2011 Feb 19.
83 New Trends in the Treatment of Schizophrenia.CNS Neurol Disord Drug Targets. 2017;16(8):900-906. doi: 10.2174/1871527316666170728165355.
84 Association study of CAG repeats in the KCNN3 gene in Israeli patients with major psychosis.Psychiatr Genet. 2003 Sep;13(3):143-50. doi: 10.1097/00041444-200309000-00002.
85 Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia.Mol Psychiatry. 2014 Sep;19(9):1017-1024. doi: 10.1038/mp.2013.138. Epub 2013 Nov 26.
86 Polymorphisms in genes implicated in dopamine, serotonin and noradrenalin metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations in psychosis.Behav Brain Funct. 2014 Jul 29;10:26. doi: 10.1186/1744-9081-10-26.
87 Troponin T levels associated with genetic variants in NOTCH2 and MTNR1B in women with psychosis.Psychiatry Res. 2017 Apr;250:217-220. doi: 10.1016/j.psychres.2017.01.030. Epub 2017 Jan 20.
88 Reduced DNA Methylation of the Oxytocin Receptor Gene Is Associated With Anhedonia-Asociality in Women With Recent-Onset Schizophrenia and Ultra-high Risk for Psychosis.Schizophr Bull. 2019 Oct 24;45(6):1279-1290. doi: 10.1093/schbul/sbz016.
89 Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort.Transl Psychiatry. 2017 Sep 26;7(9):e1240. doi: 10.1038/tp.2017.211.
90 Enzymatic activity of palmitoyl-protein thioesterase-1 in serum from schizophrenia significantly associates with schizophrenia diagnosis scales.J Cell Mol Med. 2019 Sep;23(9):6512-6518. doi: 10.1111/jcmm.14496. Epub 2019 Jul 3.
91 The possible involvement of metabotropic glutamate receptors in schizophrenia.Eur Neuropsychopharmacol. 2008 Jun;18(6):395-405. doi: 10.1016/j.euroneuro.2007.11.001. Epub 2007 Dec 11.
92 Patterns of illness and care over the 5years following onset of psychosis in different ethnic groups; the GAP-5 study.Soc Psychiatry Psychiatr Epidemiol. 2017 Sep;52(9):1101-1111. doi: 10.1007/s00127-017-1417-6. Epub 2017 Jul 5.
93 Associations between neurodevelopmental genes, neuroanatomy, and ultra high risk symptoms of psychosis in 22q11.2 deletion syndrome.Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):295-314. doi: 10.1002/ajmg.b.32515. Epub 2017 Jan 31.
94 SCN11A mRNA levels in female bipolar disorder PBMCs as tentative biomarker for distinct patient sub-phenotypes.Drug Dev Res. 2019 Dec;80(8):1128-1135. doi: 10.1002/ddr.21598. Epub 2019 Sep 9.
95 Dysphagia predicts poor outcome in late-stage Parkinson's disease.Parkinsonism Relat Disord. 2019 Jul;64:73-81. doi: 10.1016/j.parkreldis.2019.02.043. Epub 2019 Mar 2.
96 Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition.Schizophr Bull. 2013 Jul;39(4):848-56. doi: 10.1093/schbul/sbs067. Epub 2012 Apr 24.
97 Deletion at the SLC1A1 glutamate transporter gene co-segregates with schizophrenia and bipolar schizoaffective disorder in a 5-generation family.Am J Med Genet B Neuropsychiatr Genet. 2013 Mar;162B(2):87-95. doi: 10.1002/ajmg.b.32125. Epub 2013 Jan 22.
98 Dark Classics in Chemical Neuroscience: (9)-Tetrahydrocannabinol.ACS Chem Neurosci. 2019 May 15;10(5):2160-2175. doi: 10.1021/acschemneuro.8b00651. Epub 2019 Feb 22.
99 Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia.Front Psychiatry. 2019 Feb 14;10:49. doi: 10.3389/fpsyt.2019.00049. eCollection 2019.
100 Actions of Trace Amines in the Brain-Gut-Microbiome Axis via Trace Amine-Associated Receptor-1 (TAAR1).Cell Mol Neurobiol. 2020 Mar;40(2):191-201. doi: 10.1007/s10571-019-00772-7. Epub 2019 Dec 13.
101 Genetic variation of UBE3A is associated with schizotypy in a population of typical individuals.Psychiatry Res. 2019 May;275:94-99. doi: 10.1016/j.psychres.2019.03.019. Epub 2019 Mar 14.
102 A genome-wide meta-analysis identifies novel loci associated with schizophrenia and bipolar disorder.Schizophr Res. 2010 Dec;124(1-3):192-9. doi: 10.1016/j.schres.2010.09.002.
103 Association of polymorphisms in GAD1 and GAD2 genes with methamphetamine dependence.Pharmacogenomics. 2017 Jan;18(1):17-22. doi: 10.2217/pgs-2016-0101. Epub 2016 Dec 14.
104 Exosomal secretion of a psychosis-altered miRNA that regulates glutamate receptor expression is affected by antipsychotics.Neuropsychopharmacology. 2020 Mar;45(4):656-665. doi: 10.1038/s41386-019-0579-1. Epub 2019 Nov 27.
105 Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder.Mol Psychiatry. 2012 Sep;17(9):880-6. doi: 10.1038/mp.2012.73. Epub 2012 Jun 12.
106 Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders.Biol Psychiatry. 2017 Nov 15;82(10):756-765. doi: 10.1016/j.biopsych.2016.12.011. Epub 2016 Dec 16.
107 A Point Mutation in PDGFRB Causes Autosomal-Dominant Penttinen Syndrome. Am J Hum Genet. 2015 Sep 3;97(3):465-74. doi: 10.1016/j.ajhg.2015.07.009. Epub 2015 Aug 13.
108 Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes.Psychiatr Genet. 2011 Feb;21(1):1-4. doi: 10.1097/YPG.0b013e3283413382.
109 Association between RGS4 variants and psychotic-like experiences in nonclinical individuals.Eur Arch Psychiatry Clin Neurosci. 2017 Feb;267(1):19-24. doi: 10.1007/s00406-016-0676-7. Epub 2016 Feb 24.
110 Revisiting CAPE-P15 cut-off values to increase sensitivity for detecting psychotic experiences in primary care.Schizophr Res. 2020 Feb;216:507-510. doi: 10.1016/j.schres.2019.11.051. Epub 2019 Dec 5.
111 Association study between the MDR1 gene and clinical characteristics in schizophrenia.Braz J Psychiatry. 2014 Sep;36(3):227-32. doi: 10.1590/1516-4446-2013-1270. Epub 2014 Jun 10.
112 Outcomes of clients in need of intensive team care in Flexible Assertive Community Treatment in Sweden.Nord J Psychiatry. 2018 Apr;72(3):226-231. doi: 10.1080/08039488.2018.1430168. Epub 2018 Jan 26.
113 Depression and psychosis in ADCY5-related dyskinesia-part of the phenotypic spectrum?.J Clin Neurosci. 2018 Nov;57:167-168. doi: 10.1016/j.jocn.2018.08.049. Epub 2018 Aug 30.
114 Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients. Biol Psychiatry. 1987 Apr;22(4):453-62. doi: 10.1016/0006-3223(87)90167-3.
115 The effect of psychosis associated CACNA1C, and its epistasis with ZNF804A, on brain function.Genes Brain Behav. 2019 Apr;18(4):e12510. doi: 10.1111/gbb.12510. Epub 2018 Sep 10.
116 Novel evidence of the involvement of calreticulin in major psychiatric disorders.Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jun 1;37(2):276-81. doi: 10.1016/j.pnpbp.2012.02.007. Epub 2012 Feb 21.
117 Association between CCK-AR gene and schizophrenia with auditory hallucinations.Psychiatr Genet. 2007 Apr;17(2):47-53. doi: 10.1097/YPG.0b013e3280298292.
118 Novel evidence for enhanced stem cell trafficking in antipsychotic-nave subjects during their first psychotic episode.J Psychiatr Res. 2014 Feb;49:18-24. doi: 10.1016/j.jpsychires.2013.10.016. Epub 2013 Nov 5.
119 Auditory sensory gating in young adolescents with early-onset psychosis: a comparison with attention deficit/hyperactivity disorder.Neuropsychopharmacology. 2020 Mar;45(4):649-655. doi: 10.1038/s41386-019-0555-9. Epub 2019 Oct 24.
120 Genome-wide association study of atypical psychosis.Am J Med Genet B Neuropsychiatr Genet. 2013 Oct;162B(7):679-86. doi: 10.1002/ajmg.b.32164.
121 In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis.JAMA Psychiatry. 2019 Oct 1;76(10):1074-1084. doi: 10.1001/jamapsychiatry.2019.1427.
122 Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression.World J Biol Psychiatry. 2015 Jan;16(1):2-11. doi: 10.3109/15622975.2014.916414. Epub 2014 Jun 16.
123 Common SNPs in CSF2RB are associated with major depression and schizophrenia in the Chinese Han population.World J Biol Psychiatry. 2011 Apr;12(3):233-8. doi: 10.3109/15622975.2010.544328. Epub 2011 Jan 19.
124 Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N??345 young and elderly subjects.Brain Imaging Behav. 2013 Jun;7(2):102-15. doi: 10.1007/s11682-012-9199-7.
125 Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia.Int Clin Psychopharmacol. 2019 May;34(3):124-130. doi: 10.1097/YIC.0000000000000257.
126 Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits.Front Psychiatry. 2017 Dec 20;8:292. doi: 10.3389/fpsyt.2017.00292. eCollection 2017.
127 Opioid-related diagnoses and HIV, HCV and mental disorders: using Pennsylvania hospitalisation data to assess community-level relationships over space and time.J Epidemiol Community Health. 2019 Oct;73(10):935-940. doi: 10.1136/jech-2019-212551. Epub 2019 Jul 2.
128 Associations between a locus downstream DRD1 gene and cerebrospinal fluid dopamine metabolite concentrations in psychosis.Neurosci Lett. 2016 Apr 21;619:126-30. doi: 10.1016/j.neulet.2016.03.005. Epub 2016 Mar 5.
129 Methamphetamine-induced psychosis is associated with DNA hypomethylation and increased expression of AKT1 and key dopaminergic genes.Am J Med Genet B Neuropsychiatr Genet. 2016 Dec;171(8):1180-1189. doi: 10.1002/ajmg.b.32506. Epub 2016 Oct 18.
130 Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium.Mol Psychiatry. 2004 Jun;9(6):609-20, 544. doi: 10.1038/sj.mp.4001471.
131 Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis.Schizophr Res. 2009 Sep;113(2-3):308-21. doi: 10.1016/j.schres.2009.06.006. Epub 2009 Jul 1.
132 Social cognitive role of schizophrenia candidate gene GABRB2.PLoS One. 2013 Apr 24;8(4):e62322. doi: 10.1371/journal.pone.0062322. Print 2013.
133 GAD1 Gene Expression in Blood of Patients with First-Episode Psychosis.PLoS One. 2017 Jan 25;12(1):e0170805. doi: 10.1371/journal.pone.0170805. eCollection 2017.
134 Growth arrest and DNA-damage-inducible, beta (GADD45b)-mediated DNA demethylation in major psychosis.Neuropsychopharmacology. 2012 Jan;37(2):531-42. doi: 10.1038/npp.2011.221. Epub 2011 Nov 2.
135 Myoclonus-dystonia: Distinctive motor and non-motor phenotype from other dystonia syndromes.Parkinsonism Relat Disord. 2019 Dec;69:85-90. doi: 10.1016/j.parkreldis.2019.10.015. Epub 2019 Oct 22.
136 The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders.Eur Neuropsychopharmacol. 2019 Jan;29(1):137-146. doi: 10.1016/j.euroneuro.2018.10.007. Epub 2018 Nov 6.
137 Profiling of Amino Acids and Their Derivatives Biogenic Amines Before and After Antipsychotic Treatment in First-Episode Psychosis.Front Psychiatry. 2018 Apr 24;9:155. doi: 10.3389/fpsyt.2018.00155. eCollection 2018.
138 Genetic variation of GRIA3 gene is associated with vulnerability to methamphetamine dependence and its associated psychosis.J Psychopharmacol. 2018 Mar;32(3):309-315. doi: 10.1177/0269881117750153. Epub 2018 Jan 17.
139 A possible association between schizophrenia and GRIK3 polymorphisms in a multicenter sample of Scandinavian origin (SCOPE).Schizophr Res. 2009 Feb;107(2-3):242-8. doi: 10.1016/j.schres.2008.10.010. Epub 2008 Nov 20.
140 Chromosome abnormalities, mental retardation and the search for genes in bipolar disorder and schizophrenia.Neurotox Res. 2008 Oct;14(2-3):113-20. doi: 10.1007/BF03033803.
141 Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population.Neurosci Lett. 2013 Sep 13;551:58-61. doi: 10.1016/j.neulet.2013.07.017. Epub 2013 Jul 21.
142 Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity.Neuropsychopharmacology. 2019 Jan;44(2):443-454. doi: 10.1038/s41386-018-0143-4. Epub 2018 Jul 7.
143 Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.Neuron. 2015 May 20;86(4):1029-1040. doi: 10.1016/j.neuron.2015.03.063. Epub 2015 Apr 30.
144 Psychosis in frontotemporal dementia.J Alzheimers Dis. 2014;42(2):485-99. doi: 10.3233/JAD-140312.
145 Glutathione S-transferase alpha 1 risk polymorphism and increased bilateral thalamus mean diffusivity in schizophrenia.Psychiatry Res. 2012 Aug-Sep;203(2-3):180-3. doi: 10.1016/j.pscychresns.2011.12.016. Epub 2012 Sep 5.
146 A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. Am J Med Genet B Neuropsychiatr Genet. 2005 May 5;135B(1):5-9. doi: 10.1002/ajmg.b.30164.
147 Hemoglobins emerging roles in mental disorders. Metabolical, genetical and immunological aspects.Int J Dev Neurosci. 2017 Oct;61:73-85. doi: 10.1016/j.ijdevneu.2017.06.007. Epub 2017 Jul 8.
148 HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.Nat Neurosci. 2012 Sep;15(9):1245-54. doi: 10.1038/nn.3181. Epub 2012 Aug 5.
149 The association of the HLA in patients with schizophrenia, schizoaffective disorder, and in their biological relatives.Schizophr Res. 2005 Jul 15;76(2-3):195-8. doi: 10.1016/j.schres.2005.02.005.
150 Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacology. 2010 Feb;58(2):452-6. doi: 10.1016/j.neuropharm.2009.09.006. Epub 2009 Sep 10.
151 Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response.Neuroreport. 2000 Jun 26;11(9):2017-20. doi: 10.1097/00001756-200006260-00042.
152 Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. Drug Alcohol Depend. 2011 Jan 1;113(1):1-7. doi: 10.1016/j.drugalcdep.2010.06.021. Epub 2010 Aug 11.
153 Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study.Behav Brain Funct. 2010 May 28;6:27. doi: 10.1186/1744-9081-6-27.
154 Increased levels of serum leptin in the early stages of psychosis.J Psychiatr Res. 2019 Apr;111:24-29. doi: 10.1016/j.jpsychires.2019.01.006. Epub 2019 Jan 11.
155 Psychosis in Alzheimer's disease.Biol Psychiatry. 2014 Apr 1;75(7):542-52. doi: 10.1016/j.biopsych.2013.08.020. Epub 2013 Oct 6.
156 MeCP2 AT-Hook1 mutations in patients with intellectual disability and/or schizophrenia disrupt DNA binding and chromatin compaction in vitro.Hum Mutat. 2018 May;39(5):717-728. doi: 10.1002/humu.23409. Epub 2018 Mar 8.
157 The glycine transporter 1 gene (GLYT1) is associated with methamphetamine-use disorder. Am J Med Genet B Neuropsychiatr Genet. 2008 Jan 5;147B(1):54-8. doi: 10.1002/ajmg.b.30565.
158 Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis.Addict Biol. 2005 Jun;10(2):145-8. doi: 10.1080/13556210500123423.
159 Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. Pharmacogenomics J. 2006 May-Jun;6(3):179-88. doi: 10.1038/sj.tpj.6500355.
160 Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features.Schizophr Res. 2009 Apr;109(1-3):94-7. doi: 10.1016/j.schres.2009.02.009. Epub 2009 Mar 5.
161 Association of missense variants of the PRKC, apoptosis, WT1, regulator (PAWR) gene with schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):870-5. doi: 10.1016/j.pnpbp.2008.01.003. Epub 2008 Jan 11.
162 Genetic variants on 3q21 and in the Sp8 transcription factor gene (SP8) as susceptibility loci for psychotic disorders: a genetic association study.PLoS One. 2013 Aug 13;8(8):e70964. doi: 10.1371/journal.pone.0070964. eCollection 2013.
163 Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia.J Clin Psychopharmacol. 2019 Nov/Dec;39(6):575-582. doi: 10.1097/JCP.0000000000001128.
164 Evidence for rare and common genetic risk variants for schizophrenia at protein kinase C, alpha.Mol Psychiatry. 2010 Nov;15(11):1101-11. doi: 10.1038/mp.2009.96. Epub 2009 Sep 29.
165 M129V variation in the prion protein gene and psychotic disorders: relationship to neuropsychological and psychopathological measures.J Psychiatr Res. 2007 Nov;41(10):885-92. doi: 10.1016/j.jpsychires.2006.07.003. Epub 2006 Sep 1.
166 p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling.Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4717-22. doi: 10.1073/pnas.0600585103. Epub 2006 Mar 10.
167 Functional analysis of a potassium-chloride co-transporter 3 (SLC12A6) promoter polymorphism leading to an additional DNA methylation site. Neuropsychopharmacology. 2009 Jan;34(2):458-67.
168 Interaction between effects of genes coding for dopamine and glutamate transmission on striatal and parahippocampal function.Hum Brain Mapp. 2013 Sep;34(9):2244-58. doi: 10.1002/hbm.22061. Epub 2012 Mar 22.
169 Reduced expression of SP1 and SP4 transcription factors in peripheral blood mononuclear cells in first-episode psychosis.J Psychiatr Res. 2013 Nov;47(11):1608-14. doi: 10.1016/j.jpsychires.2013.07.019. Epub 2013 Aug 12.
170 Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder.Brain Res. 2006 Feb 16;1073-1074:25-37. doi: 10.1016/j.brainres.2005.12.056. Epub 2006 Jan 30.
171 Association of TLR4 (D299G, T399I), TLR9 -1486T>C, TIRAP S180L and TNF- promoter (-1031, -863, -857) polymorphisms with risk for systemic lupus erythematosus among South Indians.Lupus. 2015 Jan;24(1):50-7. doi: 10.1177/0961203314549792. Epub 2014 Sep 2.
172 Association of the iPLA2 gene with bipolar disorder and assessment of its interaction with TRPM2 gene polymorphisms.Psychiatr Genet. 2013 Apr;23(2):86-9. doi: 10.1097/YPG.0b013e32835d700d.
173 Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum.Schizophr Res. 2019 Nov;213:80-86. doi: 10.1016/j.schres.2018.10.008. Epub 2018 Nov 6.
174 Identification of genes from a schizophrenia-linked translocation breakpoint region.Genomics. 2001 Apr 1;73(1):123-6. doi: 10.1006/geno.2001.6516.
175 Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls.Transl Psychiatry. 2018 Apr 12;8(1):78. doi: 10.1038/s41398-018-0124-8.
176 Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia.Cell. 2012 Mar 2;148(5):1051-64. doi: 10.1016/j.cell.2011.12.037.
177 Association study of nonsynonymous single nucleotide polymorphisms in schizophrenia.Biol Psychiatry. 2012 Jan 15;71(2):169-77. doi: 10.1016/j.biopsych.2011.09.032. Epub 2011 Nov 10.
178 Genome-wide mediation analysis of psychiatric and cognitive traits through imaging phenotypes.Hum Brain Mapp. 2017 Aug;38(8):4088-4097. doi: 10.1002/hbm.23650. Epub 2017 May 22.
179 Psychiatric symptoms in migraine patients and their attitudes towards psychological support on stigmatization.J Clin Neurosci. 2019 Apr;62:180-183. doi: 10.1016/j.jocn.2018.11.035. Epub 2018 Nov 22.
180 A genetic association study of CSMD1 and CSMD2 with cognitive function.Brain Behav Immun. 2017 Mar;61:209-216. doi: 10.1016/j.bbi.2016.11.026. Epub 2016 Nov 25.
181 Genetic alcohol sensitivity regulated by ALDH2 and ADH1B polymorphisms is strongly associated with depression and anxiety in Japanese employees.Drug Alcohol Depend. 2015 Feb 1;147:130-6. doi: 10.1016/j.drugalcdep.2014.11.034. Epub 2014 Dec 13.
182 Discovery and validation of blood biomarkers for suicidality.Mol Psychiatry. 2013 Dec;18(12):1249-64. doi: 10.1038/mp.2013.95. Epub 2013 Aug 20.
183 Caregiver-Care Recipient Relationship Closeness is Associated With Neuropsychiatric Symptoms in Dementia.Am J Geriatr Psychiatry. 2019 Apr;27(4):349-359. doi: 10.1016/j.jagp.2018.11.010. Epub 2018 Dec 1.
184 A hypothesis for how chromosome 11 translocations cause psychiatric disorders.Genetics. 2007 Oct;177(2):1259-62. doi: 10.1534/genetics.107.077875. Epub 2007 Aug 24.
185 Examining the structure of ideas of reference in clinical and community samples.Compr Psychiatry. 2019 Aug;93:48-55. doi: 10.1016/j.comppsych.2019.06.006. Epub 2019 Jul 3.
186 Similar effect of family history of psychosis on Sylvian fissure size and auditory P200 amplitude in schizophrenic and bipolar subjects.Psychiatry Res. 2001 Nov 5;108(1):29-38. doi: 10.1016/s0925-4927(01)00113-5.
187 Increased frequency of psychosis after second-generation antiepileptic drug administration in adults with focal epilepsy.Epilepsy Behav. 2019 Aug;97:138-143. doi: 10.1016/j.yebeh.2019.06.002. Epub 2019 Jun 25.
188 The association of white matter volume in psychotic disorders with genotypic variation in NRG1, MOG and CNP: a voxel-based analysis in affected individuals and their unaffected relatives.Transl Psychiatry. 2012 Oct 9;2(10):e167. doi: 10.1038/tp.2012.82.
189 Early interventions in a US military FIRST episode psychosis program.Early Interv Psychiatry. 2018 Dec;12(6):1243-1249. doi: 10.1111/eip.12709. Epub 2018 Jul 3.
190 Serotonin transporter gene (HTTLPR) is not in linkage disequilibrium with prepubertal and early adolescent bipolarity.Biol Psychiatry. 1999 May 1;45(9):1230-3. doi: 10.1016/s0006-3223(98)00362-x.
191 Mood disorders in first- and second-generation immigrants: systematic review and meta-analysis.Br J Psychiatry. 2017 Mar;210(3):182-189. doi: 10.1192/bjp.bp.116.181107. Epub 2017 Jan 9.
192 Detection of Borna disease virus p24 RNA in peripheral blood cells from Brazilian mood and psychotic disorder patients.J Affect Disord. 2006 Jan;90(1):43-7. doi: 10.1016/j.jad.2005.10.008. Epub 2005 Dec 1.
193 AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder.Neuropsychopharmacology. 2011 Nov;36(12):2529-37. doi: 10.1038/npp.2011.141. Epub 2011 Jul 20.
194 Effects of repeated long-term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders.CNS Neurosci Ther. 2018 Jun;24(6):528-538. doi: 10.1111/cns.12810. Epub 2018 Jan 31.
195 Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia.Mol Psychiatry. 2018 Nov;23(11):2156-2166. doi: 10.1038/mp.2017.156. Epub 2017 Oct 10.
196 The epsin 4 gene is associated with psychotic disorders in families of Latin American origin.Schizophr Res. 2008 Dec;106(2-3):253-7. doi: 10.1016/j.schres.2008.09.005. Epub 2008 Oct 17.
197 Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat.Schizophr Res. 2019 Apr;206:263-270. doi: 10.1016/j.schres.2018.11.006. Epub 2018 Dec 3.
198 The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells.Carcinogenesis. 2013 Sep;34(9):2080-9. doi: 10.1093/carcin/bgt169. Epub 2013 May 20.
199 Unwell in hospital but not incapable: cross-sectional study on the dissociation of decision-making capacity for treatment and research in in-patients with schizophrenia and related psychoses.Br J Psychiatry. 2018 Aug;213(2):484-489. doi: 10.1192/bjp.2018.85. Epub 2018 Jun 18.
200 Electrodermal activation in first-episode psychotic patients and their first-degree relatives.Psychiatry Res. 1999 Oct 18;88(1):25-39. doi: 10.1016/s0165-1781(99)00071-2.
201 High rates of general practice attendance by former prisoners: a prospective cohort study.Med J Aust. 2017 Jul 17;207(2):75-80. doi: 10.5694/mja16.00841.
202 Kalirin reduction rescues psychosis-associated behavioral deficits in APPswe/PSEN1dE9 transgenic mice.Neurobiol Aging. 2017 Jun;54:59-70. doi: 10.1016/j.neurobiolaging.2017.02.006. Epub 2017 Feb 16.
203 Fronto-parietal hypo-activation during working memory independent of structural abnormalities: conjoint fMRI and sMRI analyses in adolescent offspring of schizophrenia patients.Neuroimage. 2011 Sep 1;58(1):234-41. doi: 10.1016/j.neuroimage.2011.06.033. Epub 2011 Jun 29.
204 The role of social isolation and social cognition in thought disorder.Psychiatry Res. 2018 Nov;269:56-63. doi: 10.1016/j.psychres.2018.08.048. Epub 2018 Aug 16.
205 Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).Trials. 2019 Jun 7;20(1):331. doi: 10.1186/s13063-019-3336-1.
206 The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms.Schizophr Bull. 2017 Jan;43(1):57-63. doi: 10.1093/schbul/sbw152. Epub 2016 Oct 25.
207 Where and what is the right shift factor or cerebral dominance gene? A critique of Francks et al. (2007).Laterality. 2009 Jan;14(1):3-10. doi: 10.1080/13576500802574984.
208 Pilot study for family-based association analysis of schizophrenia in a Korean population: Analysis for candidate genes positionally on chromosome 18q21.Asia Pac Psychiatry. 2015 Sep;7(3):268-75. doi: 10.1111/appy.12167. Epub 2014 Dec 12.
209 Novel NAXE variants as a cause for neurometabolic disorder: implications for treatment.J Neurol. 2020 Mar;267(3):770-782. doi: 10.1007/s00415-019-09640-2. Epub 2019 Nov 20.
210 Mitochondrial DNA sequence data reveals association of haplogroup U with psychosis in bipolar disorder.J Psychiatr Res. 2017 Jan;84:221-226. doi: 10.1016/j.jpsychires.2016.09.027. Epub 2016 Sep 30.
211 Replication of linkage with bipolar disorder on chromosome 16p in the Eastern Quebec population.Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):737-44. doi: 10.1002/ajmg.b.30673.
212 NRXN1 is associated with enlargement of the temporal horns of the lateral ventricles in psychosis.Transl Psychiatry. 2019 Sep 17;9(1):230. doi: 10.1038/s41398-019-0564-9.
213 ProtocadherinX/Y, a candidate gene-pair for schizophrenia and schizoaffective disorder: a DHPLC investigation of genomic sequence.Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):1-9. doi: 10.1002/ajmg.b.30036.
214 Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: Retrospective cohort study.Parkinsonism Relat Disord. 2019 Nov;68:95-101. doi: 10.1016/j.parkreldis.2019.10.018. Epub 2019 Oct 24.
215 Sex-specific rates of transmission of psychosis in the New England high-risk family study.Schizophr Res. 2011 May;128(1-3):150-5. doi: 10.1016/j.schres.2011.01.019. Epub 2011 Feb 18.
216 The mRNA Expression Status of Dopamine Receptor D2, Dopamine Receptor D3 and DARPP-32 in T Lymphocytes of Patients with Early Psychosis.Int J Mol Sci. 2015 Nov 6;16(11):26677-86. doi: 10.3390/ijms161125983.
217 A novel relationship for schizophrenia, bipolar and major depressive disorder Part 3: Evidence from chromosome 3 high density association screen.J Comp Neurol. 2018 Jan 1;526(1):59-79. doi: 10.1002/cne.24311. Epub 2017 Oct 16.
218 Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease.J Mol Neurosci. 2015 Sep;57(1):48-62. doi: 10.1007/s12031-015-0576-8. Epub 2015 May 17.
219 Sedentary behaviour, physical activity, cardiorespiratory fitness and cardiometabolic risk in psychosis: The PsychiActive project.Schizophr Res. 2018 May;195:142-148. doi: 10.1016/j.schres.2017.10.012. Epub 2017 Oct 21.
220 EEG 40 Hz Coherence Decreases in REM Sleep and Ketamine Model of Psychosis.Front Psychiatry. 2019 Jan 17;9:766. doi: 10.3389/fpsyt.2018.00766. eCollection 2018.
221 Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain.Synapse. 2007 May;61(5):303-9. doi: 10.1002/syn.20368.
222 Diagnostic and Prognostic Significance of DSM-5 Attenuated Psychosis Syndrome in Services for Individuals at Ultra High Risk for Psychosis.Schizophr Bull. 2018 Feb 15;44(2):264-275. doi: 10.1093/schbul/sbx055.
223 Reduced integrity of superior longitudinal fasciculus and arcuate fasciculus as a marker for auditory hallucinations in schizophrenia: A DTI tractography study.Asian J Psychiatr. 2019 Aug;44:179-186. doi: 10.1016/j.ajp.2019.07.043. Epub 2019 Jul 30.
224 Inpatient use and area-level socio-environmental factors in people with psychosis.Soc Psychiatry Psychiatr Epidemiol. 2018 Oct;53(10):1133-1140. doi: 10.1007/s00127-018-1534-x. Epub 2018 May 23.
225 The kynurenine pathway in schizophrenia and bipolar disorder.Neuropharmacology. 2017 Jan;112(Pt B):297-306. doi: 10.1016/j.neuropharm.2016.05.020. Epub 2016 May 28.
226 Poor functional recovery is better predicted than conversion in studies of outcomes of clinical high risk of psychosis: insight from SHARP.Psychol Med. 2020 Jul;50(9):1578-1584. doi: 10.1017/S0033291719002174. Epub 2019 Aug 27.
227 Synaptic vesicle 2C and its synaptic-related function.Clin Chim Acta. 2017 Sep;472:112-117. doi: 10.1016/j.cca.2017.07.029. Epub 2017 Jul 31.
228 Evaluating verbal learning and memory in patients with an at-risk mental state or first episode psychosis using structural equation modelling.PLoS One. 2018 May 10;13(5):e0196936. doi: 10.1371/journal.pone.0196936. eCollection 2018.
229 TGFB-induced factor (TGIF): a candidate gene for psychosis on chromosome 18p.Mol Psychiatry. 2007 Nov;12(11):1033-41. doi: 10.1038/sj.mp.4001997. Epub 2007 Apr 17.
230 Sleep duration and psychotic experiences in patients at risk of psychosis: A secondary analysis of the EDIE-2 trial.Schizophr Res. 2019 Feb;204:326-333. doi: 10.1016/j.schres.2018.08.006. Epub 2018 Aug 16.
231 Electrophysiological correlates of emotional scene processing in bipolar disorder.J Psychiatr Res. 2020 Jan;120:83-90. doi: 10.1016/j.jpsychires.2019.10.005. Epub 2019 Oct 8.
232 Circuit activity underlying a distinct modulator of prepulse inhibition.Psychiatry Res Neuroimaging. 2019 Jun 30;288:1-11. doi: 10.1016/j.pscychresns.2019.04.005. Epub 2019 Apr 19.
233 Longitudinal Analyses of Blood Transcriptome During Conversion to Psychosis.Schizophr Bull. 2019 Jan 1;45(1):247-255. doi: 10.1093/schbul/sby009.
234 Genetic association and functional characterization of MCPH1 gene variation in bipolar disorder and schizophrenia.Am J Med Genet B Neuropsychiatr Genet. 2019 Jun;180(4):258-265. doi: 10.1002/ajmg.b.32722. Epub 2019 Mar 11.
235 Towards a neurodynamical understanding of the prodrome in schizophrenia.Neuroimage. 2019 Apr 15;190:144-153. doi: 10.1016/j.neuroimage.2017.11.026. Epub 2017 Nov 22.
236 Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression.Am J Psychiatry. 2010 Oct;167(10):1254-63. doi: 10.1176/appi.ajp.2010.09091335. Epub 2010 Aug 16.
237 Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis.JAMA Psychiatry. 2020 Feb 1;77(2):190-200. doi: 10.1001/jamapsychiatry.2019.3501.
238 Role of MED12 in transcription and human behavior.Pharmacogenomics. 2007 Aug;8(8):909-16. doi: 10.2217/14622416.8.8.909.
239 A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia.Mol Brain. 2014 Jan 21;7:5. doi: 10.1186/1756-6606-7-5.
240 ANK3 gene expression in bipolar disorder and schizophrenia.Br J Psychiatry. 2014 Sep;205(3):244-5. doi: 10.1192/bjp.bp.114.145433. Epub 2014 May 8.
241 Upregulation of TET1 and downregulation of APOBEC3A and APOBEC3C in the parietal cortex of psychotic patients.Transl Psychiatry. 2012 Sep 4;2(9):e159. doi: 10.1038/tp.2012.86.
242 Psychotic syndrome associated with anti-Ca/ARHGAP26 and voltage-gated potassium channel antibodies.J Neuroimmunol. 2015 Sep 15;286:79-82. doi: 10.1016/j.jneuroim.2015.07.009. Epub 2015 Jul 22.
243 Common variants in the BCL9 gene conferring risk of schizophrenia.Arch Gen Psychiatry. 2011 Mar;68(3):232-40. doi: 10.1001/archgenpsychiatry.2011.1.
244 Olanzapine-induced methylation alters cadherin gene families and associated pathways implicated in psychosis.BMC Neurosci. 2014 Sep 29;15:112. doi: 10.1186/1471-2202-15-112.
245 Influence of DAOA and RGS4 genes on the risk for psychotic disorders and their associated executive dysfunctions: A family-based study.Eur Psychiatry. 2016 Feb;32:42-7. doi: 10.1016/j.eurpsy.2015.11.002. Epub 2016 Jan 21.
246 Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models.Science. 2014 Jun 6;344(6188):1178-82. doi: 10.1126/science.1253895.
247 The transcriptome landscape associated with Disrupted-in-Schizophrenia-1 locus impairment in early development and adulthood.Schizophr Res. 2019 Aug;210:149-156. doi: 10.1016/j.schres.2019.05.032. Epub 2019 Jun 13.
248 Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20(th) Century.J Psychoactive Drugs. 2019 Jul-Aug;51(3):210-217. doi: 10.1080/02791072.2019.1581961. Epub 2019 Mar 6.
249 Genetic polymorphism in DTNBP1 gene is associated with methamphetamine-induced panic disorder.J Addict Med. 2014 Nov-Dec;8(6):431-7. doi: 10.1097/ADM.0000000000000075.
250 Neuropsychiatric complications and neuroimaging characteristics after deep brain stimulation surgery for Parkinson's disease.Brain Imaging Behav. 2020 Feb;14(1):62-71. doi: 10.1007/s11682-018-9971-4.
251 Interaction between FEZ1 and DISC1 in regulation of neuronal development and risk for schizophrenia.Neuron. 2011 Nov 17;72(4):559-71. doi: 10.1016/j.neuron.2011.09.032.
252 Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology. 2005 Aug 23;65(4):603-5. doi: 10.1212/01.wnl.0000178224.81169.c2.
253 Association study between GNB1L and three major mental disorders in Chinese Han populations.Psychiatry Res. 2011 May 30;187(3):457-9. doi: 10.1016/j.psychres.2010.04.019. Epub 2010 Jun 9.
254 Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists.Bioorg Med Chem. 2018 May 1;26(8):1598-1608. doi: 10.1016/j.bmc.2018.02.005. Epub 2018 Feb 10.
255 Replication and cross-phenotype study based upon schizophrenia GWASs data in the Japanese population: support for association of MHC region with psychosis.Am J Med Genet B Neuropsychiatr Genet. 2014 Jul;165B(5):421-7. doi: 10.1002/ajmg.b.32246. Epub 2014 May 29.
256 The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders.Psychoneuroendocrinology. 2019 Apr;102:24-36. doi: 10.1016/j.psyneuen.2018.11.028. Epub 2018 Nov 22.
257 Developmentally regulated and thalamus-selective induction of leiomodin2 gene by a schizophrenomimetic, phencyclidine, in the rat.Int J Neuropsychopharmacol. 2009 Sep;12(8):1111-26. doi: 10.1017/S1461145709009997. Epub 2009 Mar 2.
258 Common variant at 16p11.2 conferring risk of psychosis.Mol Psychiatry. 2014 Jan;19(1):108-14. doi: 10.1038/mp.2012.157. Epub 2012 Nov 20.
259 Malic enzyme 2 and susceptibility to psychosis and mania.Psychiatry Res. 2007 Feb 28;150(1):1-11. doi: 10.1016/j.psychres.2006.06.001. Epub 2007 Jan 29.
260 Hippocampal CA1 region shows differential regulation of gene expression in mice displaying extremes in behavioral sensitization to amphetamine: relevance for psychosis susceptibility?.Psychopharmacology (Berl). 2011 Oct;217(4):525-38. doi: 10.1007/s00213-011-2313-5. Epub 2011 May 3.
261 Vulnerability to depressive behavior induced by overexpression of striatal Shati/Nat8l via the serotonergic neuronal pathway in mice.Behav Brain Res. 2019 Dec 30;376:112227. doi: 10.1016/j.bbr.2019.112227. Epub 2019 Sep 11.
262 Evidence of statistical epistasis between DISC1, CIT and NDEL1 impacting risk for schizophrenia: biological validation with functional neuroimaging.Hum Genet. 2010 Apr;127(4):441-52. doi: 10.1007/s00439-009-0782-y.
263 Improving Access to psychological therapies for people with severe mental illness (IAPT-SMI): Lessons from the South London and Maudsley psychosis demonstration site.Behav Res Ther. 2019 May;116:104-110. doi: 10.1016/j.brat.2019.03.002. Epub 2019 Mar 8.
264 Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors.Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13648-53. doi: 10.1073/pnas.0405310101. Epub 2004 Sep 3.
265 Association of NPAS3 exonic variation with schizophrenia.Schizophr Res. 2010 Jul;120(1-3):143-9. doi: 10.1016/j.schres.2010.04.002. Epub 2010 May 14.
266 Evidence that variation in the oligodendrocyte lineage transcription factor 2 (OLIG2) gene is associated with psychosis in Alzheimer's disease.Neurosci Lett. 2009 Sep 11;461(1):54-9. doi: 10.1016/j.neulet.2009.05.051. Epub 2009 May 27.
267 Sequence analysis of P21-activated kinase 3 (PAK3) in chronic schizophrenia with cognitive impairment.Schizophr Res. 2008 Dec;106(2-3):265-7. doi: 10.1016/j.schres.2008.08.021. Epub 2008 Sep 20.
268 An inherited duplication at the gene p21 Protein-Activated Kinase 7 (PAK7) is a risk factor for psychosis.Hum Mol Genet. 2014 Jun 15;23(12):3316-26. doi: 10.1093/hmg/ddu025. Epub 2014 Jan 28.
269 Schizophrenia is a later-onset feature of PCDH19 Girls Clustering Epilepsy.Epilepsia. 2019 Mar;60(3):429-440. doi: 10.1111/epi.14678. Epub 2019 Mar 3.
270 Association studies and gene expression analyses of the DISC1-interacting molecules, pericentrin 2 (PCNT2) and DISC1-binding zinc finger protein (DBZ), with schizophrenia and with bipolar disorder.Am J Med Genet B Neuropsychiatr Genet. 2009 Oct 5;150B(7):967-76. doi: 10.1002/ajmg.b.30926.
271 Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry. 2007 Jul;164(7):1105-14. doi: 10.1176/ajp.2007.164.7.1105.
272 Defective PITRM1 mitochondrial peptidase is associated with A amyloidotic neurodegeneration. EMBO Mol Med. 2016 Mar 1;8(3):176-90. doi: 10.15252/emmm.201505894.
273 Calcineurin A gamma and B gene expressions in the whole blood in Japanese patients with schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):1000-4. doi: 10.1016/j.pnpbp.2008.01.013. Epub 2008 Jan 31.
274 Parvalbumin promoter hypermethylation in postmortem brain in schizophrenia.Epigenomics. 2018 May;10(5):519-524. doi: 10.2217/epi-2017-0159. Epub 2018 Apr 24.
275 Single-cell trajectory analysis of human homogenous neurons carrying a rare RELN variant.Transl Psychiatry. 2018 Jul 19;8(1):129. doi: 10.1038/s41398-018-0177-8.
276 The utility of SELENBP1 gene expression as a biomarker for major psychotic disorders: replication in schizophrenia and extension to bipolar disorder with psychosis.Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):686-9. doi: 10.1002/ajmg.b.30664.
277 Screening of an endothelial cDNA library identifies the C-terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations.Arthritis Res Ther. 2005;7(4):R896-903. doi: 10.1186/ar1759. Epub 2005 May 20.
278 A promoter variant of SHANK1 affects auditory working memory in schizophrenia patients and in subjects clinically at risk for psychosis.Eur Arch Psychiatry Clin Neurosci. 2012 Mar;262(2):117-24. doi: 10.1007/s00406-011-0233-3. Epub 2011 Sep 7.
279 SOBP is mutated in syndromic and nonsyndromic intellectual disability and is highly expressed in the brain limbic system. Am J Hum Genet. 2010 Nov 12;87(5):694-700. doi: 10.1016/j.ajhg.2010.10.005. Epub 2010 Oct 28.
280 Family-based association study of lithium-related and other candidate genes in bipolar disorder.Arch Gen Psychiatry. 2008 Jan;65(1):53-61. doi: 10.1001/archgenpsychiatry.2007.15.
281 Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder.Hum Mol Genet. 2011 Dec 15;20(24):4786-96. doi: 10.1093/hmg/ddr416. Epub 2011 Sep 9.
282 Mapping cortical morphology in youth with velocardiofacial (22q11.2 deletion) syndrome.J Am Acad Child Adolesc Psychiatry. 2011 Mar;50(3):272-282.e2. doi: 10.1016/j.jaac.2010.12.002. Epub 2011 Jan 14.
283 TCF4 gene polymorphism and cognitive performance in patients with first episode psychosis.Schizophr Res. 2014 Jan;152(1):124-9. doi: 10.1016/j.schres.2013.10.038. Epub 2013 Nov 22.
284 Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain.Schizophr Res. 2014 Oct;159(1):107-13. doi: 10.1016/j.schres.2014.07.004. Epub 2014 Aug 12.
285 Tet1 overexpression leads to anxiety-like behavior and enhanced fear memories via the activation of calcium-dependent cascade through Egr1 expression in mice.FASEB J. 2018 Jan;32(1):390-403. doi: 10.1096/fj.201601340RR. Epub 2017 Sep 12.
286 De novo variant of TRRAP in a patient with very early onset psychosis in the context of non-verbal learning disability and obsessive-compulsive disorder: a case report.BMC Med Genet. 2018 Nov 13;19(1):197. doi: 10.1186/s12881-018-0711-9.
287 Hereditary spastic paraparesis and psychosis.Eur J Neurol. 2006 Aug;13(8):874-9. doi: 10.1111/j.1468-1331.2006.01379.x.